MANNELLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.180
EU - Europa 2.997
AS - Asia 696
AF - Africa 16
SA - Sud America 4
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.896
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.169
RU - Federazione Russa 1.219
IT - Italia 477
PL - Polonia 342
IE - Irlanda 268
SE - Svezia 258
SG - Singapore 205
CN - Cina 198
HK - Hong Kong 164
CH - Svizzera 149
DE - Germania 80
UA - Ucraina 62
FI - Finlandia 58
IN - India 52
GB - Regno Unito 48
JO - Giordania 42
TR - Turchia 17
CI - Costa d'Avorio 14
CA - Canada 11
FR - Francia 11
ES - Italia 9
VN - Vietnam 8
NL - Olanda 6
BR - Brasile 4
KR - Corea 4
RO - Romania 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BE - Belgio 2
BG - Bulgaria 2
AU - Australia 1
BY - Bielorussia 1
EG - Egitto 1
EU - Europa 1
JP - Giappone 1
KZ - Kazakistan 1
MY - Malesia 1
NZ - Nuova Zelanda 1
SD - Sudan 1
TH - Thailandia 1
Totale 7.896
Salva come PNG Salva come JPEG
Città #
Santa Clara 831
Fairfield 514
Warsaw 340
Ashburn 284
Chandler 283
Dublin 268
Woodbridge 231
Seattle 222
Houston 192
Cambridge 187
Singapore 155
Wilmington 148
Bern 147
Altamura 96
Hong Kong 96
Lawrence 96
Jacksonville 93
Ann Arbor 82
Florence 80
Princeton 76
Beijing 69
Moscow 51
Buffalo 47
Mumbai 43
Boston 39
New York 39
Medford 38
Boardman 37
San Diego 36
Shanghai 36
Bremen 28
Kent 25
Rome 21
Helsinki 16
Abidjan 14
Izmir 13
Milan 12
Falls Church 10
Hillsboro 10
Yubileyny 10
Los Angeles 9
London 8
Norwalk 8
Sesto Fiorentino 8
Toronto 8
Andover 7
Manresa 7
Dearborn 6
Fiesole 6
Pian di Scò 6
Salerno 6
Washington 6
West Jordan 6
Munich 5
Verona 5
Auburn Hills 4
Bologna 4
Catania 4
Dong Ket 4
Fontebuona 4
Frankfurt Am Main 4
Lappeenranta 4
Napoli 4
Paris 4
Pune 4
San Jose 4
Siena 4
Bari 3
Faenza 3
Genoa 3
Guangzhou 3
Hangzhou 3
Hefei 3
Leawood 3
Naples 3
Parma 3
Pavia 3
Phoenix 3
Prato 3
Redwood City 3
Rochester 3
Seoul 3
Shenzhen 3
São Paulo 3
Acquaviva delle Fonti 2
Ankara 2
Brescia 2
Brussels 2
Castelliri 2
Chengdu 2
Chennai 2
Cortona 2
Dubai 2
Fuzhou 2
Gambettola 2
Groningen 2
Hounslow 2
Kilburn 2
Kolkata 2
Manchester 2
Totale 5.247
Salva come PNG Salva come JPEG
Nome #
CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. 243
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 238
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. 214
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 178
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 149
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 138
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 134
Progress in Italy in control and elimination of measles and congenital rubella. 133
Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia 132
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 131
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 127
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 125
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 125
Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. 125
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 124
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 121
A life-threatening ruxolitinib discontinuation syndrome 121
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 118
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 117
Progress in Italy in control and elimination of measles and congenital rubella. 116
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 115
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. 111
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey 110
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 109
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. 107
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 107
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. 107
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 105
Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma 102
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 102
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. 100
Validation of the Mayo alliance prognostic system for mastocytosis 99
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML 98
Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. 96
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial 96
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 95
Diagnosis of a T-lineage acute Lymphoblastic leukemia through digitalized cell analysis of the pleural effusion 94
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 91
Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. 90
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. 90
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. 88
Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models 88
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 87
Implementation of the Plan for Elimination of Measles and Congenital Rubella Infection in Tuscany: evidence of progress towards phase II of measles control 85
Atypical acute leukemia early after liver transplantation. 84
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. 82
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial 82
SUBCUTANEOUS CAMPATH-1H IN REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: FEASIBILITY AND EFFICACY 81
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts 78
Progress towards measles and rubella elimination in Tuscany,l Italy: the role of population seroepidemiological profile 77
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 77
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 76
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 76
Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. 75
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 75
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 71
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 71
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 68
High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients. 68
High dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-Myl) in relapsed or refractory AML patients 68
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 68
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 67
Sieroepidemiologia della rosolia in Toscana: strategie di vaccinazione per il recupero dei suscettibili. 64
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia 63
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 63
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 61
Implementazione del piano per l'eliminazione del morbillo e della rosolia congenita in Toscana: progressi verso la seconda fase di controllo dell'infezione. 61
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 60
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 60
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 59
High response rates and reduced first dose reactions with subcutaneous alemtuzumab in patients with relapsed and refractory CLL 58
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 58
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 57
Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report 56
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 53
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series 53
Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management 51
Diagnostic and therapeutic challenges in mast cell sarcoma 51
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 49
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 47
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 45
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 41
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 40
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 38
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 37
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases 37
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 31
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms 28
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 26
Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature 23
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 16
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 11
Totale 8.022
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.334
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.334
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020917 0 0 0 0 137 148 143 149 128 80 103 29
2020/2021716 44 56 75 80 42 80 28 60 67 83 50 51
2021/2022520 17 38 48 14 32 26 23 49 32 15 95 131
2022/20231.512 118 278 94 95 92 225 159 77 135 19 44 176
2023/2024765 31 62 98 52 86 104 46 133 15 48 50 40
2024/20252.640 152 431 316 707 1.034 0 0 0 0 0 0 0
Totale 8.022